Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Common Equity: 2011-2025

Historic Common Equity for Adma Biologics (ADMA) over the last 11 years, with Sep 2025 value amounting to $431.2 million.

  • Adma Biologics' Common Equity rose 85.94% to $431.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $431.2 million, marking a year-over-year increase of 85.94%. This contributed to the annual value of $349.0 million for FY2024, which is 158.14% up from last year.
  • As of Q3 2025, Adma Biologics' Common Equity stood at $431.2 million, which was up 8.25% from $398.3 million recorded in Q2 2025.
  • Adma Biologics' 5-year Common Equity high stood at $431.2 million for Q3 2025, and its period low was $100.4 million during Q3 2022.
  • In the last 3 years, Adma Biologics' Common Equity had a median value of $188.3 million in 2024 and averaged $245.9 million.
  • Its Common Equity has fluctuated over the past 5 years, first fell by 11.03% in 2023, then skyrocketed by 158.14% in 2024.
  • Quarterly analysis of 5 years shows Adma Biologics' Common Equity stood at $141.2 million in 2021, then climbed by 7.65% to $152.0 million in 2022, then decreased by 11.03% to $135.2 million in 2023, then skyrocketed by 158.14% to $349.0 million in 2024, then soared by 85.94% to $431.2 million in 2025.
  • Its Common Equity stands at $431.2 million for Q3 2025, versus $398.3 million for Q2 2025 and $373.4 million for Q1 2025.